



Receipt

Practitioner's Docket No. MPI00-540OMNIM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Holtzman, Douglas A., et al.

Application No.: 09/811,088

Group No.: 1646

Filed: March 16, 2001

Examiner: Elizabeth Kemmerer

For: NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC,  
DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER USES

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application is/are:
  - a. This Transmittal (2 pages);
  - b. Request for Corrected Filing Receipt (2 pages);
  - c. Copy of marked-up Filing Receipt (2 pages);
  - d. Power of Attorney and Correspondence Address Indication Form (1 page);
  - e. Statement Under 37 CFR 3.73(b) (1 page);
  - f. Notice of Recordation of Assignment (2 pages);
  - g. Assignment to Millennium Pharmaceuticals, Inc. (6 pages); and
  - h. Return Postcard.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No. \_\_\_\_\_

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: January 11, 2006

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-540OMNIM

**PETITION FOR EXTENSION OF TIME**

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a \_\_\_\_\_ month extension:

Fee: \$0.00

If an additional extension of time is required, please consider this a petition therefor.

**FEE FOR CLAIMS**

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)		OTHER THAN A SMALL ENTITY
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra	Rate	Addit. Fee
Total	0	Minus	0	=	0	\$50.00	\$0.00
Indep.	0	Minus	0	=	0	\$200.00	\$0.00
First Presentation of Multiple Dependent Claims			0			\$360.00	\$0.00
						Total Addit. Fee	\$0.00

Total additional fee for claims required \$0.00

**FEE PAYMENT**

5. Charge Account No. 501668 the sum of \$0.00 (which includes the extension fee and the \$0.00 additional fee for claims). \$0.00

**FEE DEFICIENCY**

6. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

7. Correspondence Address  
Direct all future correspondence to:

**Customer Number 30405**

OR

Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
40 Landsdowne Street  
Cambridge, MA 02139

January 11, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By

Mario Cloutier  
Mario Cloutier

Registration No. 57,225  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 577-3522  
Facsimile – (617) 551-8820

Practitioner's Docket No. MPI00-540OMNIM

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Holtzman, Douglas A., et al.  
Application No.: 09/811,088 Group No.: 1646  
Filed: March 16, 2001 Examiner: Elizabeth Kemmerer  
For: NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC,  
DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER USES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

*Note: The PTO will not correct the filing receipt until the application is complete (in other words, the applicant files a response to the notice to file missing parts).*

2. There is an error with respect to the following data, which is:

[ ] incorrectly entered

[X] omitted.

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10\*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office. (703) 872-9306

Signature \_\_\_\_\_

Date: January 11, 2006

Sean Hunziker

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-5400MNIM

*Error in*

1. ☐ Applicant's name
2. ☐ Applicant's address
3. ☐ Title
4. ☐ Filing Date
5. ☐ Serial Number
6. ☐ Foreign/PCT Application Re:
7. ☒ Other – Priority Data is incomplete

*Correct data*

- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
7. Priority Data – Filed Priority Data as follows:  
The application is a continuation-in-part (and claims the benefit of priority under 35 USC 120) of the following applications:  
U.S. Application Serial No. 09/712,726 (filed 11/14/00), which application claims priority from U.S. Serial No. 08/820,364 (filed 3/12/97), now abandoned.  
U.S. Application Serial No. 09/757,421 (filed 1/10/01), which application claims priority from U.S. Serial No. 08/843,652 (filed 4/16/97), now abandoned.  
U.S. Application Serial No. 08/843,651 (filed 4/16/97).  
U.S. Application Serial No. 09/354,809 (filed 7/16/99), a divisional of U.S. Application Serial No. 08/938,365 (filed 9/26/97), now issued.

3. If any fee is due with this request, charge Deposit Account No. 501668.

January 11, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By: \_\_\_\_\_

Mario Cloutier  
Registration No. 57,225  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 577-3522  
Facsimile – (617) 551-8820



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/811,088	03/16/2001	1645	1110	MP12000-540OMNI(M)	30	35	3

Jean M. Silveri  
Millennium Pharmaceuticals, Inc.  
75 Sidney Street  
Cambridge, MA 02139

REC'D MAR 07 2002



CONFIRMATION NO. 8287

UPDATED FILING RECEIPT



\*OC00000007562376\*

Date Mailed: 03/01/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

## Applicant(s)

Douglas A. Holtzman, Jamaica Plain, MA;  
David P. Gearing, Victoria, AUSTRALIA;  
Yang Pan, Bellevue, WA;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/712,726 11/14/2000, which application claims priority

## Foreign Applications

If Required, Foreign Filing License Granted 05/01/2001

Projected Publication Date: 06/06/2002

Non-Publication Request: No

Early Publication Request: No

## Title

Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses

## Preliminary Class

Add ↓

From US Application Serial No. 08/020,364 (filed 3/12/97), now abandoned.  
- US Application Serial No. 09/757,421 (filed 1/10/01) which application claim priority from U.S. Serial No. 08/043,052 (filed 4/16/97), now abandoned.  
- US Application Serial No. 08/843,651 (filed 11/16/99)  
- US Application Serial No. 09/354,809 (filed 7/16/99), a divisional of U.S. Application Serial No. 08/938,365 (filed 9/26/97), now issued.

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**


The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



PTO/SB/81 (04-05)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

Application Number	09/811,088
Filing Date	March 16, 2001
First Named Inventor	Douglas A. Holtzman
Title	NOVEL GENES ENCODING PROTEINS HAV
Art Unit	1646
Examiner Name	Elizabeth Kemmerer
Attorney Docket Number	MPI00-540OMNIM

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number:

30405

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

30405

☐ Firm or  
Individual Name

Address

City

State

Zip


Country

Telephone

Email

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)**SIGNATURE of Applicant or Assignee of Record**


Signature		Date	January 11, 2006
Name	Jean M. Silveri	Telephone	617-679-7336
Title and Company	Associate General Counsel. Millennium Pharmaceuticals, Inc.		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ \*Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Millennium Pharmaceuticals, Inc.Application No./Patent No.: 09/811,088 Filed/Issue Date: March 16, 2001Entitled: NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER USESMillennium Pharmaceuticals, Inc., a a Delaware corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 011949, Frame 0815, or for which a copy thereof is attached.

OR

B ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Jean M. Silveri  
Signature  
Jean M. Silveri  
Printed or Typed Name

January 11, 2006  
Date  
617-679-7336  
Telephone Number

Associate General Counsel


Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



mp 12000-5480 mhi (u)



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SEPTEMBER 13, 2001

PTAS

MILLENNIUM PHARMACEUTICALS, INC.  
JEAN M. SILVERI  
75 SIDNEY STREET  
CAMBRIDGE, MA 02139



\*101773549A\*

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/29/2001

REEL/FRAME: 011949/0815  
NUMBER OF PAGES: 6

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

HOLTZMAN, DOUGLAS A.

DOC DATE: 06/15/2001

ASSIGNOR:

GEARING, DAVID P.

DOC DATE: 06/22/2001

ASSIGNOR:

PAN, YANG


DOC DATE: 06/19/2001

ASSIGNEE:

MILLENNIUM PHARMACEUTICALS, INC.  
75 SIDNEY STREET  
CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 09811088  
PATENT NUMBER:

FILING DATE: 03/16/2001  
ISSUE DATE:



011949/0815 PAGE 2

SHARON LATIMER, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS



07-11-2001

Substitute Form PTO-1595  
Attorney Docket No.: 07334-324001  
Client's Ref. No.: MPI2000-5400MNI

REC



ET

101773549

JUN 29 2001

Commissioner for Patents: Please record the attached original document(s) or copy(ies).	
1. Name of conveying party(ies): Douglas A. Holtzman, David P. Gearing, Yang Pan and Additional name(s) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies): MILLENNIUM PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139  MMD 6/29/01 Additional names/addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: Execution Date: June 15, 2001; June 22, 2001; and June 19, 2001, respectively	
4. Application number(s) or patent number(s): If this document is being filed with a new application, the execution date of the application is: A. Patent Application No(s): 09/811,088 B. Patent No(s): Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
5. Name/address of party to whom correspondence concerning document should be mailed: Jean M. Silveri Millennium Pharmaceuticals, Inc. 75 Sidney Street Cambridge, MA 02139	6. Total number of applications/patents involved: 1 7. Total fee (37 CFR §3.41): \$40 <input checked="" type="checkbox"/> Enclosed <input type="checkbox"/> Authorized to charge Deposit Account. 8. Deposit Account No.: 06-1050 Please apply any additional charges, or any credits, to our Deposit Account No. 06-1050.
DO NOT USE THIS SPACE	
9. Statement and Signature: <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>  Anita L. Meiklejohn, Ph.D. Reg. No. 35,283 Name of Person Signing  John W. Dreeman Signature  6/29/01 Date  Total number of pages including coversheet, attachments and document: 5	

20282897.doc

07/10/2001 DBYRNE 00000065 09811088

01 FC:581

40.00 OP

## CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL856745894US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner of Patents, Washington, D.C. 20231.

June 29, 2001  
Date of Deposit

Signature

Samantha Bell  
Typed Name of Person Signing Certificate

**Practitioner's Docket No. MPI2000-540OMNI**

**PATENT**

For: U.S. Rights  
For: U.S. Application  
By: Inventors

### **ASSIGNMENT OF INVENTION**

In consideration of the payment by ASSIGNEE to ASSIGNORS of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration,

#### **ASSIGNORS:**

Douglas A. Holtzman  
821 Centre Street, No. 6  
Jamaica Plain, MA 02130  
Nationality: United States of America

Yang Pan  
5308 135<sup>th</sup> Place SE  
Bellevue, WA 98006  
Nationality: Peoples' Republic of China

David P. Gearing  
6 Julianne Court  
East Doncaster, Victoria 3109  
Australia  
Nationality: British

hereby sell, assign and transfer to

#### **ASSIGNEE:**

MILLENNIUM PHARMACEUTICALS, INC.  
75 Sidney Street  
Cambridge, MA 02139  
State of Incorporation: Delaware

and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and all foreign countries in and to inventions described in the patent application entitled:

### **NOVEL GENES ENCODING PROTEINS HAVING PROGNASTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER USES**

and which is found in (37 C.F.R. section 3.21) U.S. application no. 09/811,088 filed on March 16, 2001 and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to letters patent any reissue or re-examination thereof; said invention, application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and

legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent. We hereby acknowledge that this assignment, being of the entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein.

ASSIGNORS hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNORS further covenant for ourselves and our executors and administrators that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNORS, their executors and administrators and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof and to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of substitution, reissue, divisional or continuation applications and preliminary or other statements.

AND, we do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

IN WITNESS WHEREOF, I have hereunto set hand and seal this  
15th day of JUNE, 2001.

Date: X 6/15/01

X Douglas Holtzman  
Signature of Douglas A. Holtzman

**NOTARIZATION ACCOMPANYING ASSIGNMENT**


State/Commonwealth of Massachusetts  
County of Middlesex

Before me this 15th day of JUNE 2001, personally appeared the above named **Douglas A. Holtzman**, to me known to be the person described in, and who executed the foregoing assignment instrument and acknowledged to me that he executed the same of his own free will for the purpose therein expressed.

Simonne Corriveau  
Signature of Notary Public  
SIMONNE CORRIVEAU  
Print Name  
My Commission expires: 9/1/2006

IN WITNESS WHEREOF, I have hereunto set hand and seal this 22nd day  
of JUNE, 2001.

Date: 22 June 2001

  
Signature of David P. Gearing

+ Sheryl Ayurved, 135 Mitchell St. East Brunswick VIC 3057  
Witness Address Australia

+ Melrose Padua, 3 Coburn Pl, Kings Park, Vic 3021  
Witness Address Australia

IN WITNESS WHEREOF, I have hereunto set hand and seal this 19<sup>TH</sup> day  
of JUNE, 2001.


Date: 6/19/01

Yang Pan  
Signature of Yang Pan

NOTARIZATION ACCOMPANYING ASSIGNMENT

State/Commonwealth of WASHINGTON  
County of KING

Before me this 19<sup>TH</sup> day of JUNE, 2001, personally appeared the above  
named **Yang Pan**, to me known to be the persons described in, and who executed the foregoing  
assignment instrument and acknowledged to me that he executed the same of his own free will  
for the purpose therein expressed.



Corinne Harmon  
Signature of Notary Public  
CORINNE HARMON  
Print Name  
My Commission expires: 03-22-03